EcoDrugPlus

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSACIG00000005978
Gene Symbol: EGLN1
1 Cross references
216 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 3

Ensembl ID : ENSACIG00000005177
Gene Symbol: EGLN3
1 Cross references
200 Possible Orthologues:

Endothelial Pas Domain Protein 1b

Ensembl ID : ENSACIG00000007054
Gene Symbol: EPAS1B
1 Cross references
211 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSACIG00000012205
Gene Symbol: ECE1
1 Cross references
231 Possible Orthologues:

Endothelin Receptor Type Aa

Ensembl ID : ENSACIG00000016660
Gene Symbol: EDNRAA
1 Cross references
205 Possible Orthologues:

Endothelin Receptor Type Ab

Ensembl ID : ENSACIG00000016594
Gene Symbol: EDNRAB
1 Cross references
201 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSACIG00000009070
Gene Symbol: EDNRB
1 Cross references
178 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSACIG00000018784
Gene Symbol: EDNRB
1 Cross references
200 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSACIG00000002702
Gene Symbol: EZH2
1 Cross references
240 Possible Orthologues:

Epidermal Growth Factor Receptor A (Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog, Avian)

Ensembl ID : ENSACIG00000019884
Gene Symbol: EGFRA
1 Cross references
212 Possible Orthologues:

Epoxide Hydrolase 2, Cytoplasmic

Ensembl ID : ENSACIG00000020608
Gene Symbol: EPHX2
1 Cross references
204 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSACIG00000014118
Gene Symbol: ERBB2
1 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).